埼玉医科大学雑誌 第47巻 第2号 (令和3年3月) 91-95頁◇論文(図表を含む全文)は,PDFファイルとなっています

PDF (786 KB)

Case Report
Systemic Epstein-Barr virus-positive T-cell lymphoma in an adult patient
with chronic myeloid leukemia receiving a tyrosine kinase inhibitor

Yuka Tanaka1), Tomoe Anan1), Takayuki Tabayashi1)*, Michihide Tokuhira1),
Shuji Momose2), Jun-ichi Tamaru2), Masahiro Kizaki1)
1)Department of Hematology, Saitama Medical Center, Saitama Medical University
2)Department of Pathology, Saitama Medical Center, Saitama Medical University


Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma (TCL) of childhood rarely develops in adults. The first case of sys-temic EBV-positive TCL, which occurred in an adult patient with chronic myeloid leukemia who was treated with a tyrosine kinase inhibitor (TKI), is reported. The patient was treated with nilotinib (TKI) for two years. He presented with a two-month history of cervical lymphadenopathy, common cold symptoms and had high titers of EBV in peripheral blood. A lymph node biopsy showed CD8-positive atypical T cells with EBV infection. Because of the pathological finding of EBV-positive T-cell lymphoma and status of EBV reactivation, we diagnosed him with systemic EBV-positive TCL. Conventional chemotherapy followed by hematopoietic stem cell transplantation was a valuable therapeutic option for this patient. TKIs are likely to inhibit T-cell activation and prolifera-tion, and might be involved in the onset of systemic EBV-positive TCL.

J Saitama Medical University 2021; 47(2): 91-95
(Received June 19, 2020/Accepted September 19, 2020)

Keywords: tyrosine kinase inhibitor, Nilotinib, Epstein-Barr virus, systemic Epstein-Barr virus-positive T-cell lymphoma of childhood





(C) 2021 The Medical Society of Saitama Medical University